Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen is supported by a differentiated pipeline across retinal disease, cell therapy, and vaccines, with the strongest fundamental case coming from its modifier gene therapy platform and novel biologic programs in large unmet-need indications. The company’s lead assets have de-risking clinical readouts and milestones ahead: OCU400’s Ph3 trial in retinitis pigmentosa completed enrollment of 140 patients in 1Q26 with topline data expected in 1Q27, while OCU410 showed 31% reduction in GA lesion area and 27% reduction in EZ loss versus controls. Financially, the company reported runway into 2028 after its debt offering, and its modeled product rNPV of $4.1B against net debt of $17.7M underscores meaningful embedded value if execution and regulatory progress continue.

Ocugen is facing a weaker fundamental outlook because the baseline lesion imbalance may require additional patient data and the Stargardt program has been conservatively delayed to 2030 from 2028, signaling meaningful execution risk in a key pipeline asset. The company’s gene therapy opportunity also appears constrained by market size, since Stargardt disease has only about 100K patients in the US and EU versus roughly 300K for retinitis pigmentosa and 2-3M for geographic atrophy. Even with no changes to RP and GA valuation, the delay reduces near-term confidence in the pipeline and led to a lower 12-month valuation of $9.50 per diluted share from $10.00.